Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.

Bhamidipati, Deepak; Subbiah, Vivek

Bhamidipati, Deepak; Subbiah, Vivek.

Affiliation

Bhamidipati D; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: vsubbiah@mdanderson.org.

Trends Cancer ; 9(3): 237-249, 2023 03.

Article de En | MEDLINE | ID: mdl-36494311

Sujet(s)
Mots clés

cancer clinical trials; next-generation sequencing; targeted therapy; tissue-agnostic

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs gastro-intestinales Limites: Humans Langue: En Journal: Trends Cancer Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google